top of page


Genetic insights for better managment

Together with our partners we provide state of art technology for genetic testing related to oncology. We provide both liquid biopsy genetic testing and classical testing.
Genetic testing for hereditary and somatic cancers can provide life-changing results in affected patients and their relatives, accompanied by potential actionable steps for genetic-related cancers. With many different applications of genetic testing to detect and care for cancer, we can guide you in selecting the right options to enhance the treatment of your patients suffering from hereditary cancers. Having identified genetic variants associated with oncological diseases in more than 200 different genes, we can provide a comprehensive range to foster cancer diagnosis, prognosis, treatment selection, and monitoring.

Image by National Cancer Institute



Breast cancer is the most common type of cancer in woman constituting around 25% of all females cases. Mutations in BRCA1 and BRCA2 can increase the risk of developing cancer.
No. of genes:2
Type: Germline
Details: Panel includes next-generation sequencing.


TumorMatix is a cutting-edge, non-invasive liquid biopsy test, fortified with artificial intelligence, designed for optimal therapy selection in patients diagnosed with colorectal cancer and non-small cell lung cancer (NSCLC). Administered via a straightforward blood draw, TumorMatix is painless for the patient and successfully navigates some of the challenges of tumor biopsy including tumor inaccessibility, hospitalization after surgery, and failure to represent tumor heterogeneity.
Leveraging our proprietary AI technology, TumorMatix meticulously analyzes minute quantities of circulating tumor DNA (ctDNA) — cell-free DNA released from primary and metastatic tumor sites into the patient's bloodstream.
TumorMatix proficiently detects genetic mutations that drive cancers or are associated with resistance to treatment, and concurrently assesses microsatellite instability (MSI). The unique test design ensures that TumorMatix provides invaluable information and guidance on targeted therapy selection, thus making cancer treatment more precise and advantageous for your patient. With TumorMatix, step into the future of cancer care, where AI-driven precision meets therapeutic efficacy.

TumorMatix FFPE

It is our All-in-one
Validated cancer panel for analysis of 591 key cancer-specific genes from tissue biopsy samples and genomic DNA
TumorMatix profiling is the most comprehensive gene panel available for optimised detection of tumour-specific genomic alterations. The oncology panel is optimised for formalin-fixed paraffin embedded (FFPE) or fresh-frozen tissue samples, as well as genomic DNA samples, to deliver accurate genomic information on the status of clinically relevant driver mutations. This solid tumour panel uniformly and reproducibly covers the entire exons of about 600 characterised cancer genes, including tumour activators, tumour suppressors and biomarkers for drug resistance.

Embryonic Stem Cells

Intrested in our panels? Please get in touch

Thanks for submitting! We’ll send you a price quote soon.

bottom of page